Search for Abstracts Find by Title, Author or Description Year Abstracts - 2022 - 2021 - 2020 - 2019 - 2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009 Tags AB Applied Basic Science Basic Science BT Clinical Clinical-Chemotherapy-SSA-Biologics Clinical-PRRT-Nuclear Clinical-Surgical-Applied_Pathology OT Other P Population Science Poster T Trials In Progress Search Reset Order by Title Alphabetical Title Reverse Alphabetical Most Recent First Oldest First Most popular first Last modified first BT01 – Targeting Glycogen Synthase Kinase-3 as a Therapy for Pediatric Neuroendocrine Tumor Published in 2014 Listed under BT Download Balamurugan BT02 – Drug Discovery for Atypical Pulmonary Carcinoid Using a Library of Targeted Agents Published in 2014 Listed under BT Download Chong BT03 – Pathologic Classification of Pulmonary Carcinoid Cell Lines Published in 2014 Listed under BT Download Chong BT04 – Whole Exome Sequencing Identifies Somatic ATRX Mutations in Pheochromocytomas and Paragangliomas Published in 2014 Listed under BT Download Fishbein BT05 – Cadherin 17 is Frequently Expressed by “Sclerosing Variant†Pancreatic Neuroendocrine Tumor Published in 2014 Listed under BT Download Johnson BT06 – Molecular Profiling of Small Intestinal Neuroendocrine Tumour Published in 2014 Listed under BT Download Karpathakis BT07 – Induction of Serotonin Production in Human Pancreatic Neuroendocrine Tumors by Tryptophan Hydroxylase-1 Published in 2014 Listed under BT Download Kelly BT08 – Targeted-Alpha-Therapy with Astatine-211-Meta-Astatobenzylguanidine ( 211 At-MABG) in the Treatment of Pheochromocytoma Published in 2014 Listed under BT Download Makvandi BT09 – A Practical Method to Determine the Site of Unknown Primary in Metastatic Neuroendocrine Tumors Published in 2014 Listed under BT Download Maxwell BT10 – Receptor for Hyaluron-Mediated Motility Isoform B Protects Pancreatic Neuroendocrine Tumors From Anoikis Published in 2014 Listed under BT Download Pages BT11 – Exploration and Targeting of Neuroendocrine Cancer Tumorigenic Signal Transduction Published in 2014 Listed under BT Download Pozo BT12 – Autophagy Activation, a Survival Mechanism for pNETs Treated with mTOR Inhibitors Published in 2014 Listed under BT Download Thomas BT13 – Molecular Profiling of Advanced Stage Neuro Endocrine Tumors (NETs): The Fox Chase Cancer Center (FCCC) Experience Published in 2014 Listed under BT Download Vijayvergia C01 – Incidence, Prevalence and Survival of Patients with Small Bowel Neuroendocrine Tumors (MGC) Excluding Appendiceal Tumors: A Northern Ireland (NI) Study Over 25 years Published in 2014 Listed under Clinical Download Ardill C02 – Poor Prognosis in Spontaneous Gastrinoma When Additional Hormones and Peptides are Secreted Published in 2014 Listed under Clinical Download Ardill C03 – Health-Related Quality of Life (HRQL) in Patients With Uncontrolled Neuroendocrine Tumor (NET) Symptoms Published in 2014 Listed under Clinical Download Beaumont C04 – Long Term Effects of Surgical Resection of Pheochromocytoma or Paraganglioma on Body Weights: A Retrospective Cohort Study Published in 2014 Listed under Clinical Download Bennett C05 – Theranostics with I-131/I-123 Meta-Iodobenzylguanidine (MIBG) in Stage IV Advanced Malignant Neuroendocrine Tumors Published in 2014 Listed under Clinical Download Campeau C06 – Antitumor Effects with Lanreotide Autogel/Depot (LAN) in Patients with Metastatic Enteropancreatic (EP) Neuroendocrine Tumors (NETs): Interim Results of the CLARINET Extension Study Published in 2014 Listed under Clinical Download Caplin C07 – Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin Analogs Published in 2014 Listed under Clinical Download Chauhan C08 – Chemotherapy for Locally Advanced and Metastatic Pulmonary Carcinoid Tumors Published in 2014 Listed under Clinical Download Chong C09 – A Phase II Study of Axitnib in Advanced Carcinoid Tumors Published in 2014 Listed under Clinical Download Cives C10 – Use of Molecular Profiling to Guide Treatment Decisions in Patients with Neuroendocrine Tumors Published in 2014 Listed under Clinical Download Cutler C11 – The Prognostic Significance of Lymph Node Ratio in Carcinoid Tumors Published in 2014 Listed under Clinical Download Flatow C12 – Response to Capecitabine and Temozolomide in an Adolescent Female with Metastatic, Non-functional Pancreatic Neuroendocrine Tumor Published in 2014 Listed under Clinical Download Gilbert C13 – Small Intestine Neuroendocrine Tumors: Frequently of Unrecognized Primary Site and Multifocal Published in 2014 Listed under Clinical Download Javeed C14 – Elevated Serum Pancreastatin is an Indicator of Hepatic Metastasis in Patients with Small Bowel Neuroendocrine Tumors Published in 2014 Listed under Clinical Download Khan C15 – A Multi-Gene Transcript Blood Molecular Signature for Gut Neuroendocrine Tumors (NETs) Delineates Surgical Efficacy Published in 2014 Listed under Clinical Download Kidd C16 – Prognostic Significance of the Extent of Lymph Node Metastases in Small Intestinal Neuroendocrine Tumors Published in 2014 Listed under Clinical Download Kim C17 – Comparison of the Effectiveness of 68Ga-DOTATATE PET/CT and 111In-Octreotide SPECT in Patients with Somatostatin Positive Neuroendocrine Tumor Published in 2014 Listed under Clinical Download Kumar C18 – DNA-repair Defects in Pancreatic Neuroendocrine Tumors and Potential Clinical Applications Published in 2014 Listed under Clinical Download Liu C19 – Long-term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Liver Metastases Published in 2014 Listed under Clinical Download Partelli C20 – A Prospective, Multi-Institutional Phase II Study of Pazopanib and Depot Octreotide in Advanced, Well-Differentiated Neuroendocrine Tumors Published in 2014 Listed under Clinical Download Phan C21 – Prognostic Significance of CDKN1B (p27) Expression in Gastroenteropancreatic Neuroendocrine Tumors Published in 2014 Listed under Clinical Download Qian C22 – Evaluation of the Features of Long Term Hematologic Toxicity in Neuroendocrine Patients Treated with Peptide Receptor Radionuclide Therapy(PRRT) Published in 2014 Listed under Clinical Download Richter C23 – Weight Gain After Acid Control in Zollinger Ellison Syndrome Published in 2014 Listed under Clinical Download Riff C24 – Phase I, Open-Label, Randomized, Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Octreotide Subcutaneous (sc) Depot Versus Octreotide Long-Acting Repeatable (OCT-LAR) in Healthy Volunteers Published in 2014 Listed under Clinical Download Roberts C25 – Phase I, Open-Label, Randomized, Bioequivalence Study of Octreotide (OCT) Long-Acting Repeatable (LAR) Reconstituted in a New Vehicle (NV) vs OCT LAR 30 mg (current vehicle) Published in 2014 Listed under Clinical Download Roberts C26 – Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) vs. Placebo in Patients with Enteropancreatic Neuroendocrine Tumors: Results From the CLARINET Core Study Published in 2014 Listed under Clinical Download Ruszniewski C27 – Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients with Carcinoid Syndrome (CS): Results From the SymNET Study Published in 2014 Listed under Clinical Download Ruszniewski C28 – Ki 67 and/or Mitotic Count in the Czech Neuroendocrine Tumour Registry Published in 2014 Listed under Clinical Download Sedlackova C29 – Octreotide LAR Among Elderly Patients With Neuroendocrine Tumors: A Survival Analysis of SEER-Medicare Data Published in 2014 Listed under Clinical Download Shen C30 – Pancreastatin Predicts Survival in Neuroendocrine Tumors Published in 2014 Listed under Clinical Download Sherman C31 – Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET): A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data Published in 2014 Listed under Clinical Download Strosberg C32 – Real-World First-Line Treatment Patterns Among US Carcinoid Syndrome Patients Published in 2014 Listed under Clinical Download Sun C33 – The Healthcare and Economic Impact of Diarrhea on US Patients with Carcinoid Syndrome Published in 2014 Listed under Clinical Download Broder C34 – Preoperative Metyrosine Improves Cardiovascular Outcomes For Patients Undergoing Surgery For Pheochromocytoma and Paraganglioma Published in 2014 Listed under Clinical Download Wachtel C35 – Adjuvant Intraoperative Post-Dissection Tumor Bed Chemotherapy – A Novel Approach in Treating Midgut Neuroendocrine Tumors Published in 2014 Listed under Clinical Download Wang C36 – In Vitro Chemotherapy Profiling of Well-Differentiated Midgut Neuroendocrine Tumors (NETs) Based on Individual Patient Tumor Biomarkers Analysis Published in 2014 Listed under Clinical Download Wang C37 – Reappraisal of Lymphatic Mapping for Midgut Neuroendocrine Patients Undergoing Cytoreductive Surgery Published in 2014 Listed under Clinical Download Wang C38 – Telotristat Etiprate (TE) in a Subset of Patients with Carcinoid Heart Disease Included in Two Phase 2 Trials for Carcinoid Syndrome Published in 2014 Listed under Clinical Download Wheeler C39 – Telotristat Etiprate in a Subset of Carcinoid Syndrome Patients who have High Levels of Urinary 5-hydroxyindoleacetic Acid and Frequent Flushing Published in 2014 Listed under Clinical Download Wheeler C40 – Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET) Published in 2014 Listed under Clinical Download Wolin C41 – Everolimus (EVE) for the Treatment of Advanced Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled, Multicenter Phase 3 Trial (RADIANT-3) Published in 2014 Listed under Clinical Download C42 – Early Recurrence of Carcinoid Valvulopathy After Valve Replacement Published in 2014 Listed under Clinical Download Zacks C43 – Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal Tract Published in 2014 Listed under Clinical Download Zemek O01 – Neuroendocrine tumor (NET) Impact on Quality of Life (QOL) Patient Experience From the First Global NET Patient Survey: A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals Published in 2014 Listed under Other Download Goldstein OT02 – Netter-1: First Pivotal Multicenter Phase III Study Evaluating 177 Lu-dotatate in Midgut Neuroendocrine Tumors Published in 2014 Listed under OT Download Sierra 5 10 15 20 25 30 50 100
